Effect of Valproic Acid on proliferation and apoptosis of esophageal cancer cells and study on its antitumor activity mechanism
YANG Jing-rong1 LIU Ya-ming1 ZHANG Jin-can2 ZENG Zhi-yong1▲
1.Department of Cardiothoracic Surgery, the 900th Hospital of the Joint Support Force (the Former Fuzhou General Hospital of Nanjing Military Region), Fujian Province, Fuzhou 350025, China;
2.Fuzong Clinical College of Fujian Medical University, Fujian Province, Fuzhou 350025, China
Abstract:Objective To explore the effect of Valproic Acid (VPA) on proliferation and apoptosis of esophageal cancer cells,and expression of Bcl-2,Caspase protein,as well as molecular mechanisms of signal transduction pathways. Methods ECa-109 cell line of esophageal cancer was cultured with PRMI1640 medium, and grouped according to solvent control and solubility gradient:blank control and VPA 0.25 mmol/L, 0.5 mmol/L, 1.0 mmol/L, 2.0 mmol/L, 4.0 mmol/L.After treating cells for 24, 48 and 72 hours according to different drug concentrations, the changes of esophageal cancer ECa-109 cells were observed, and different detection methods were used to detect the changes of cell viability, apoptosis and cycle of esophageal cancer ECa-109 cells.Western Blot was used to detect CyclinD1, p21, Survivin, Bcl-2,Caspase protein and PI3K/Akt and MAPK signal transduction pathway changes. Results VPA showed different extent changes on vitality, proliferation, differentiation of ECa-109 cells, could induce cell apoptosis by inducing cell cycle arrest.Western Blot experiment results showed that VPA could affect the expression of Bcl-2, Survivin and Caspase proteins in ECa-109 cells.VPA could significantly reduce the expression level of CyclinD1 protein in ECa-109 cells and increase the expression of p21 protein, which influenced the phosphorylation of key proteins such as AKT and MAPK in the signaling pathway PI3K/Akt and MAPK pathway. Conclusion VPA has an effect on the proliferation and apoptosis of esophageal cancer cells and it is concentration-dependent, which can affect the growth of esophageal cancer cells through the signaling pathways of multiple protein kinase pathways, the expression of survival proteins, the expression of PI3K/Akt and MAPK signaling pathways.
杨鲸蓉; 柳亚明; 张锦灿; 曾志勇. 丙戊酸对食管癌细胞增殖凋亡的影响及其抗肿瘤活性机制的研究[J]. 中国当代医药, 2020, 27(15): 4-9.
YANG Jing-rong; LIU Ya-ming; ZHANG Jin-can; ZENG Zhi-yong. Effect of Valproic Acid on proliferation and apoptosis of esophageal cancer cells and study on its antitumor activity mechanism. 中国当代医药, 2020, 27(15): 4-9.
Wahaib K,Beggs AE,Campbell H,et al.Panobinostat:A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma[J].Am J Health Syst Pharm,2016,73(7):441-450.
[5]
Conte M,Palma RD,Altucci L.HDAC inhibitors as epigenetic regulators for cancer immunotherapy[J].Int J Biochem Cell Biol,2018,98:65-74.
[6]
Carolina V D A,Julia H,César C,et al.Epigenetic priming in cancer initiation[J].Trends Cancer,2018,4(6):408-417.
[7]
Knipstein J,Gore L.Entinostat for treatment of solid tumors and hematologic malignancies[J].Expert Opin Investig Drugs,2011,20(10):1455-1467.
[8]
Ozaki T,Wu D,Sugimoto H,D,et al.Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage[J].Cell Death Dis,2019,4(4):e610.
[9]
Lopez G,Bill KL,Bid HK,et al.HDAC8,a potential therapeutic target for the treatment of malignant peripheral nerve sheath tumors (MPNST)[J].PLoS One,2015,10(7):e133302.
[10]
Saito T,Nishida K,Furumatsu T,et al.Histone deacetylase inhibitors suppress mechanical stress-induced expression of RUNX-2 and ADAMTS-5 through the inhibition of the MAPK signaling pathway in cultured human chondrocytes[J].Osteoarthritis Cartilage,2013,21(1):165-174.
[11]
Yoon S,Eom GH.HDAC and HDAC inhibitor:from cancer to cardiovascular diseases[J].Chonnam Med J,2016,52(1):1-11.
[12]
Yang H,Maddipoti S,Quesada A,et al.Analysis of class Ⅰand Ⅱ histone deacetylase gene expression in human leukemia[J].Leuk Lymphoma,2015,56(12):3426-3433.
[13]
Glaser KB.HDAC inhibitors:Clinical update and mechanism-based potential[J].Biochem Pharmacol,2007,74(5):659-671.
[14]
Xu J,Zhou JY,Wei WZ,et al.Sp1-mediated TRAIL induction in chemosensitization[J].Cancer Res,2008,68(16):6718-6726.
[15]
Fulda S.Modulation of TRAIL-induced apoptosis by HDAC inhibitors[J].Curr Cancer Drug Targets,2008,8(2):132-140.
[16]
Zhou H,Cai Y,Liu D,et al.Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1/Cip1 and p19INK4d upregulation in hepatocellular carcinoma[J].Cell Prolif,2018,51(3):e12447.
[17]
Arts J,King P,Marien A,et al.JNJ-26481585,a novel"second-generation" oral histone deacetylase inhibitor,shows broad-spectrum preclinical antitumoral activity[J].Clin Cancer Res,2009,15(22):6841-6851.
[18]
Witt O,Sand K,Pekrun A.Butyrate induced erythroid differentiation of human K562 cells involves inhibition of ERK and activation of p38 MAP kinase pathways[J].Blood,2000,95(7):2391-2396.
[19]
Peng Z,Guo Z,Ying W,et al.Histone deacetylase inhibitors inhibit the proliferation of gallbladder carcinoma cells by suppressing AKT/mTOR signaling[J].PLoS One,2015,10(8):e136193.